Primus In News
Precision oncology gains ground as India clears targeted cancer therapies
25-12-2025
Nilaya Varma, Group CEO and Co-Founder,Primus Partners, highlights that the approvals represent a major step toward integrating outcome-based precision medicine into routine cancer care, with combination immunotherapies improving treatment outcomes for patient groups that previously had limited options.
Explore Related Insights
- We Need Higher Level Of Education In Terms Of Both Access And Quality To Be Delivered: Raghav Gupta, Coursera
- How to Get Business and Economy Back
- Novartis Vymada patent revoked, generics set to slash prices by 70%
- Tiruppur in trouble? What is ailing this Rs 70,000-crore textile cluster from scaling up
